According to the company, the implantation demonstrated significant improvements in both distance and near vision. Credit: Peakstock / Shutterstock.

Samsara Vision has announced positive intermediate-term visual and safety results from the implantation of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in late-stage age-related macular degeneration (AMD) patients six months post-surgery.

According to the company, the implantation demonstrated significant improvements in both distance and near vision, with manageable safety outcomes and minimal impact on corneal endothelium cell density.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The study reported substantial gains in best-corrected distance visual acuity (BCDVA), with 97.1%, 68.6%, and 51.4% of operated eyes experiencing at least one, two, and three-line improvements, respectively.

The subjects’ ability to read at a near distance increased from 28.6% at baseline to 97.1% at six months. Corrected near visual acuity also improved by approximately three lines after surgery.

The retrospective study, which supported the use of implantation in CE Mark-referenced countries, involved 35 subjects aged 55 years or older.

The patients were treated at the University Federico II in Naples, or the Policlinico Gemelli Hospital in Rome, Italy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Subjects underwent a rehabilitation programme to “optimise” visual outcomes, which included eight 90-minute sessions over six months. The programme focused on enhancing various visual skills.

The study also found no significant changes in intraocular pressure or anterior chamber depth, with the mean change in corneal endothelial cell density at six months being -280.7 cells/mm².

Samsara Vision CEO and president Thomas Ruggia said: “Already, 19 CE-referenced countries have implanted the SING IMT in more than 400 patients, with greater than 63% of surgeons performing multiple procedures, signalling increasing physician confidence and enthusiasm for the procedure.

“We’re gratified that this study confirms the effectiveness and safety of the SING IMT and believe our novel device will become the standard of care for patients blinded in their central vision by AMD.”

SING IMT is approved for subjects aged 55 years and older in CE-referenced countries and is under investigation in the US.